When you say current trials you should really say current trial. Marker really only has the one PII AML trial currently running. The BCM PI trials will not move the needle as they have basically done what they intended. Support the advancement of MultiTAA into future later stage trials. They stated in the past that their plan was to focus on getting the AML trial up and running before moving the pipeline forward because at the time of the merger that was their best shot at an approval. The only thing wrong with that is that now they only have one trial and should any of the results be worse than expected there is nothing else to fall back on. With the initiation of more trials they will now have multiple shots on goal which should help limit any further fall in SP should the AML data be received poorly by the market. Regardless of any of this it is never a bad thing to have multiple trials up and running. I mean, how many bio companies make it with just one trial?
Marker is paying for this trial as they will for any future trials. You can't expect them to just sit on their hands and wait for a SP rebound before they take any action to add value to the company. More trials = more value. Obviously that means an increase in expenses but that's just how things work. Remember that the full PII AML trial will cost just shy of $25M to run the whole thing. On top of that CPRIT gave them a grant of $13M for the AML trial effectively freeing up $12M for Marker to allocate elsewhere. This pancreatic trial is only going to be 25 patients. The cost should be very minimal in the grand scheme of things and the data that comes from it should help them gain a partner and move it into a pivotal PII. People have been wanting a BP partnership for a while and what BP wants is a promising treatment for solid tumors.
News 
Market Data 
Discover 
AI
